| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| Other Sizes |
| Targets |
7-Iodo-7-deaza-2'-deoxyguanosine does not have a specific biological target as it is a synthetic nucleoside analog used as a building block for DNA synthesis. The compound can be enzymatically converted to the corresponding triphosphate, which can then be incorporated into DNA by DNA polymerases during sequencing reactions. The 7-deaza modification enhances the stability of the glycosidic bond and reduces stacking interactions.
|
|---|---|
| ln Vitro |
In vitro activity of 7-Iodo-7-deaza-2'-deoxyguanosine is demonstrated by its utility as a substrate for DNA polymerases in DNA synthesis and sequencing reactions. The compound can be used to prepare fluorescent nucleotide derivatives for incorporation into oligonucleotides. Its activity is assessed by its ability to be incorporated into DNA and to serve as a substrate for enzymatic modification.
|
| ln Vivo |
In vivo activity is not applicable to 7-Iodo-7-deaza-2'-deoxyguanosine as it is a chemical reagent for research use only, not a therapeutic agent. The compound is not intended for administration to living organisms.
|
| Enzyme Assay |
In vitro enzyme assays for 7-Iodo-7-deaza-2'-deoxyguanosine involve evaluating its incorporation into DNA by DNA polymerases. The compound can be enzymatically converted to the corresponding triphosphate, which is then used as a substrate in DNA polymerase assays. Incorporation efficiency is assessed by measuring the extension of primers or by sequencing reactions.
|
| Cell Assay |
In vitro cellular assays are not applicable to 7-Iodo-7-deaza-2'-deoxyguanosine. The compound is used exclusively in chemical and enzymatic synthesis reactions for the production of modified DNA and oligonucleotides, which can subsequently be used in cellular assays. The compound itself is not tested directly on cells.
|
| Animal Protocol |
In vivo animal experiments are not applicable to 7-Iodo-7-deaza-2'-deoxyguanosine. The compound is a research chemical used in oligonucleotide synthesis and is not intended for in vivo administration.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are not applicable to 7-Iodo-7-deaza-2'-deoxyguanosine as it is a synthetic intermediate, not a therapeutic agent. The compound is not intended for systemic administration.
|
| Toxicity/Toxicokinetics |
7-Iodo-7-deaza-2'-deoxyguanosine is not intended for human therapeutic use, and toxicological data are not applicable as it is a research chemical. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
7-Iodo-7-deaza-2'-deoxyguanosine (CAS#: 172163-62-1) has the molecular formula C11H13IN4O4 and a molecular weight of 392.15. Its IUPAC name is 2-amino-7-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-iodo-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one. Purity is ≥98%. The compound is also known as 7-Deaza-7-Iodo-2'-deoxyguanosine.
|
| Molecular Formula |
C11H13IN4O4
|
|---|---|
| Molecular Weight |
392.15
|
| Exact Mass |
391.998
|
| CAS # |
172163-62-1
|
| PubChem CID |
135405252
|
| Appearance |
Solid powder
|
| Density |
2.5±0.1 g/cm3
|
| Boiling Point |
679.9±65.0 °C at 760 mmHg
|
| Flash Point |
365.0±34.3 °C
|
| Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
| Index of Refraction |
1.919
|
| LogP |
0.35
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
448
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1[C@@H]([C@H](O[C@H]1N2C=C(C3=C2N=C(NC3=O)N)I)CO)O
|
| InChi Key |
TVQBNMOSBBMRCZ-RRKCRQDMSA-N
|
| InChi Code |
InChI=1S/C11H13IN4O4/c12-4-2-16(7-1-5(18)6(3-17)20-7)9-8(4)10(19)15-11(13)14-9/h2,5-7,17-18H,1,3H2,(H3,13,14,15,19)/t5-,6+,7+/m0/s1
|
| Chemical Name |
2-amino-7-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodo-3H-pyrrolo[2,3-d]pyrimidin-4-one
|
| Synonyms |
7-Deaza-7-Iodo-2'-deoxyguanosine; 7-Iodo-7-deaza-2'-deoxyguanosine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~318.8 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5500 mL | 12.7502 mL | 25.5004 mL | |
| 5 mM | 0.5100 mL | 2.5500 mL | 5.1001 mL | |
| 10 mM | 0.2550 mL | 1.2750 mL | 2.5500 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
